FTC sets sights on new defendants, adds sham litigation claim in AndroGel pay-for-delay suit
In its second suit alleging an illegal agreement to delay a generic version of the testosterone drug AndroGel, the US Federal Trade Commission this time targeted AbbVie — the branded drug’s...To view the full article, register now.
Already a subscriber? Click here to view full article